Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2026)

Aquestive Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $141.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 38.04% year-over-year to $141.1 million in Q1 2026; TTM through Mar 2026 was $558.8 million, a 29.59% increase from a year earlier, with the FY2025 full-year figure at $160.4 million, up 58.17% from the prior year.
• Liabilities and Shareholders Equity eased to $141.1 million in Q1 2026 per AQST's latest filing, from $160.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $163.6 million in Q3 2025 and bottomed at $51.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $93.7 million (2025), against an average of $92.7 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 111.35% in 2024 and fell 21.07% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $57.1 million in 2022, then advanced by 0.61% to $57.4 million in 2023, then soared by 76.64% to $101.4 million in 2024, then soared by 58.17% to $160.4 million in 2025, then slipped by 12.03% to $141.1 million in 2026.
• Per Business Quant, the three latest AQST Liabilities and Shareholders Equity figures stand at $141.1 million (Q1 2026), $160.4 million (Q4 2025), and $163.6 million (Q3 2025).